Lacroix H, Sculier J P
Service de pneumologie, hôpital G-R-Laennec, centre hospitalier universitaire de Nantes, France.
Bull Cancer. 1990;77(10):997-1005.
The EORTC Lung Cancer Working Party investigates various chemotherapeutic regimens in patients with bronchogenic cancer. Within 12 years our Group has conducted 8 international co-operative studies in patients with non small cell lung cancer. We have demonstrated that Cis-platin was an active agent and its activity increases in association with Etoposide, mainly in limited disease. Lastly, we tested regimens including Carboplatin. This agent does not improve results in terms of objective response. We are now testing regimens including radiotherapy after chemotherapy in limited disease.
欧洲癌症研究与治疗组织肺癌工作组对支气管癌患者的各种化疗方案进行了研究。在12年的时间里，我们的团队对非小细胞肺癌患者进行了8项国际合作研究。我们已经证明顺铂是一种有效的药物，并且其活性与依托泊苷联合使用时会增强，主要用于局限性疾病。最后，我们测试了包括卡铂在内的方案。就客观缓解率而言，这种药物并没有改善治疗效果。我们目前正在测试在局限性疾病中化疗后联合放疗的方案。
